Ligand Pharmaceuticals Reports Strong Q1 2026 Results, Reaffirms Full-Year Guidance

summarizeSummary

Ligand Pharmaceuticals reported strong first-quarter 2026 financial results, with royalty revenue up 56% year-over-year and adjusted net income growing 30%, while reaffirming its full-year guidance.

check_boxKey Events

• Strong First Quarter Financial Performance

  Ligand Pharmaceuticals reported total revenues of $51.7 million for Q1 2026, a 14% increase year-over-year. Royalty revenue surged by 56% to $43.0 million, primarily driven by Filspari, Ohtuvayre, and Capvaxive. Adjusted net income grew 30% to $34.6 million, or $1.63 per diluted share, compared to $26.6 million, or $1.33 per diluted share, in Q1 2025.

• Full-Year Guidance Reaffirmed

  The company reaffirmed its 2026 full-year financial guidance, which was previously raised on April 27, 2026, following the announced acquisition of XOMA Royalty Corporation. This includes anticipated adjusted earnings per diluted share of $8.50 to $9.50 and total revenue of $270 million to $310 million.

• Key Royalty Asset Milestones

  The company highlighted the full FDA approval of Filspari for focal segmental glomerulosclerosis (FSGS) in April 2026, making it the first and only FDA-approved medicine for this rare kidney disease and its largest royalty contributor. Updates on other partner programs, including positive Phase 3 results for Qtorin rapamycin and Breakthrough Device Designation for AVIM Therapy, were also noted.

auto_awesomeAnalysis

Ligand Pharmaceuticals delivered robust first-quarter results, driven by exceptional royalty revenue growth, and reaffirmed its previously raised full-year financial guidance. The significant increase in adjusted net income and royalty revenue indicates strong operational performance and successful execution of its royalty aggregation strategy. The reaffirmation of guidance, which incorporates the recent XOMA Royalty acquisition, provides confidence in the company's outlook and the integration of the new assets.